DHFB
GSK icon

Dixon Hubard Feinour & Brown’s GSK GSK Stock Holding History

Dixon Hubard Feinour & Brown’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,764
Closed -$293K – 195
2017
Q3 		$293K Buy
5,764
+240
+4% +$12.2K 0.08% 147
2017
Q2 		$298K Buy
5,524
+1,500
+37% +$80K 0.09% 144
2017
Q1 		$212K Buy
+4,024
New +$204K 0.06% 162

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dixon Hubard Feinour & Brown's GSK Position: Q4 2017 in Review

Dixon Hubard Feinour & Brown sold out of GSK (GSK) in Q4 2017, closing a stake of 5,764 shares — an estimated $293K sold.

Dixon Hubard Feinour & Brown first reported a position in GSK in Q1 2017 and held it in 3 quarters. The position peaked at $298K in Q2 2017. 763 funds tracked by Wall St. Rank hold GSK as of Q4 2017.

  • Dixon Hubard Feinour & Brown reported no remaining GSK position as of Q4 2017 after selling out during the quarter.
  • Dixon Hubard Feinour & Brown sold 5,764 GSK shares in Q4 2017, an estimated $293K.
  • Dixon Hubard Feinour & Brown first reported a position in GSK in Q1 2017 and held it in 3 quarters.
  • Dixon Hubard Feinour & Brown's GSK position peaked at $298K in Q2 2017.
  • 763 funds tracked by Wall St. Rank held GSK as of Q4 2017.

Based on Dixon Hubard Feinour & Brown's 13F filing for Q4 2017, filed 20 Feb 2018.